Questions to Ask Before Joining an IBD Clinical Trial

The best questions before joining an IBD clinical trial turn a broad study description into a complete treatment, safety, burden, cost, and exit plan. The HHS Office for Human Research Protections provides a participant checklist covering purpose, risks, alternatives, care, costs, and worsening disease. Use the consent form and protocol calendar to record answers. Ask the study coordinator about operations and the investigator about medical rules. Ask your regular gastroenterologist how the trial compares with approved care and your own disease history. A clear answer should be specific to the study, not a general promise about research.

Ask what every treatment group receives

Find out the study's purpose, phase, treatment groups, randomization ratio, blinding, doses, background medicine, and duration. The National Institutes of Health explains that protocols define eligibility, procedures, treatment, protections, and information collection. Ask what researchers already know and what the trial is designed to discover.

If placebo or an active comparator is possible, ask for your chance of each assignment in ordinary numbers. Confirm what treatment continues in every group, when assignment can be revealed, and whether an open-label extension exists. Placebo and possible suboptimal treatment were leading concerns in a global IBD patient study, so study-specific details belong at the start of the conversation.

Ask how eligibility will be verified

Clarify the difference between preliminary matching and formal screening. Ask which records, blood tests, stool samples, imaging, endoscopy, medication history, and timing rules determine eligibility. The NIH screening guidance explains that formal screening may obtain new tests or samples after the required consent process.

Ask what happens if screening fails, who pays for procedures, and whether clinically important findings will be returned. IBD trial experts identify restrictive criteria, mismatch between symptoms and endoscopic inflammation, washouts, and procedure burden as recurring enrollment problems in IBD research. Never change prescribed treatment solely to improve eligibility without both clinicians involved. Record the exact timing rules.

Ask about worsening IBD and urgent care

Request the protocol's definition of treatment failure and its plan for rescue medication, urgent unblinding, hospitalization, withdrawal, and return to standard care. Identify daytime and after-hours contacts and ask what symptoms require emergency care. The HHS volunteer checklist recommends asking what happens if the condition worsens and who provides medical treatment for research-related injury.

Ask how the study team communicates with your GI and who makes decisions outside study hours. The FDA informed consent guidance requires disclosure of foreseeable risks, alternatives, contacts, and voluntary participation. The answer should cover every treatment group, including placebo or comparator. Ask who can authorize rescue treatment.

Ask for the full burden and cost

Obtain the visit calendar and add preparation, recovery, travel, diaries, sample collection, missed work or school, and caregiver time. A preference study found that time, endoscopy frequency, placebo exposure, open-label access, GI involvement, and compensation affected predicted willingness to join IBD trials. Ask which remote or local options are guaranteed.

Request a written cost breakdown separating research expenses, routine care billed to insurance, deductibles, copays, travel, lodging, meals, parking, and childcare. The National Cancer Institute explains the usual distinction between sponsor-paid research costs and routine patient-care costs. Clarify reimbursement timing and injury-related costs. Include caregiver time and unpaid work leave.

Ask about leaving and what happens afterward

Participation is voluntary under FDA clinical trial guidance. Ask how to stop treatment or all participation, which final safety assessments are requested, and what happens to collected data and stored samples. FDA guidance explains that data gathered before withdrawal generally remain in the study record under data-retention rules.

Finally, ask about post-trial treatment, open-label extension, treatment assignment, personal test results, aggregate findings, and record transfer to your GI. Write the answers next to the relevant consent sections. The most useful question list ends with a treatment transition that works whether you complete the study, screen fail, withdraw early, or need rescue care.

Before signing, sort unanswered items by who owns them: coordinator, investigator, billing office, privacy contact, or your GI. Send each question to the responsible person and keep the written response with the consent form. The NIH encourages participants to prepare questions and record answers. An unanswered question that could change your decision deserves resolution before the first research procedure.

Repeat this review when the protocol or consent changes because new procedures, risks, costs, or timelines can alter the original decision.